{
    "organizations": [],
    "uuid": "343fa4e24b28dd7b93c61a35521b57add26cf84e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cantargia-european-patent-for-soli/brief-cantargia-european-patent-for-solid-tumours-remains-in-force-idUSFWN1PD1JB",
    "ord_in_thread": 0,
    "title": "BRIEF-Cantargia: European Patent For Solid Tumours Remains In Force",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - CANTARGIA AB:\n* CANTARGIA‘S EUROPEAN PATENT FOR SOLID TUMOURS REMAINS IN FORCE\n* ‍EPO HAS REJECTED OPPOSITION AND CANTARGIA‘S PATENT IS THUS MAINTAINED WITH UNCHANGED CLAIMS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-19T15:38:00.000+02:00",
    "crawled": "2018-01-20T17:49:03.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "cantargia",
        "ab",
        "cantargia",
        "european",
        "patent",
        "solid",
        "tumour",
        "remains",
        "force",
        "rejected",
        "opposition",
        "cantargia",
        "patent",
        "thus",
        "maintained",
        "unchanged",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}